Sosei Group Corp

Sosei Group Corp

Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,960.00
  • Today's Change-15.00 / -0.50%
  • Shares traded636.50k
  • 1 Year change+143.62%
  • Beta1.6083
Data delayed at least 20 minutes, as of Jun 09 2023 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sosei Group Corporation is a holding company primarily engaged in the biopharmaceutical business. The pharmaceutical business is engaged in the research, development and sales of medicines, the management of regenerative medical funds, the investment in bio venture companies related to regenerative medicine, the overseas development by licensing, the promotion of commercialization, the structural analysis of GPCR, the initial lead compound creation, the candidate search by proprietary StaR technology, as well as structural base of new drugs using GPCR related basic technology drug discovery, screening, promotion of antibody drug research and development.

  • Revenue in JPY (TTM)15.39bn
  • Net income in JPY1.05bn
  • Incorporated1990
  • Employees202.00
  • Location
    Sosei Group Corp11F, PMO Hanzomon, 2-1, Koji-machiCHIYODA-KU 102-0083JapanJPN
  • Phone+81 352103290
  • Fax+81 352103291
  • Websitehttps://soseiheptares.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
ispace Inc989.24m-11.40bn123.31bn220.00------124.65-211.47-211.4718.35-43.55----------------55.88---1,152.22--1.36-97.841.53--46.74---180.75------
Mochida Pharmaceutical Co Ltd103.26bn6.65bn128.40bn1.54k18.760.96113.781.24177.78177.782,778.763,470.180.64142.033.47--4.134.865.025.9453.3752.206.447.363.41----41.67-6.28-0.6644-37.09-5.9214.62-1.21
Zeria Pharmaceutical Co Ltd68.38bn6.20bn133.65bn1.74k17.951.6910.821.95140.14140.141,548.071,484.790.52741.534.14--4.793.377.415.4072.3771.459.086.520.75156.270.429441.0314.871.1556.418.305.403.30
Sawai Group Holdings Co Ltd200.34bn12.67bn146.04bn2.97k11.550.72434.790.729288.73288.734,567.634,604.670.56151.473.03--3.601.144.951.5631.2636.926.412.241.2287.950.255880.413.373.58144.81-2.0110.060.00
Kissei Pharmaceutical Co Ltd67.49bn10.53bn150.98bn1.83k12.760.69310.242.24228.30228.301,463.584,204.650.29391.682.96--4.633.215.023.4747.9752.3915.7611.105.20--0.007636.533.23-1.83-18.523.083.7410.76
KAKEN PHARMACEUTICAL CO., LTD.72.98bn5.44bn168.55bn1.16k25.411.0121.052.31144.37144.371,942.573,636.170.44032.193.69--
JCR Pharmaceuticals Co Ltd34.34bn3.77bn177.74bn816.0045.443.2830.735.1830.1630.16275.36418.050.35760.53612.57--3.949.636.6614.6774.1374.3411.0319.320.819--0.303126.30-32.7710.77-74.004.2053.6725.21
Takara Bio Inc78.14bn16.01bn200.97bn1.67k12.551.799.712.57132.97132.97648.94931.930.63811.905.29--13.1111.7815.0913.3657.2963.9020.5420.224.6210,270.500.008624.1415.4319.32-19.3346.9729.8756.32
Tsumura & Co140.04bn16.48bn217.69bn3.92k13.160.85957.781.55215.57215.571,832.133,299.430.37460.7382.49--4.654.985.646.0348.7653.8212.4112.743.53--0.226430.978.103.51-12.502.596.410.00
Sosei Group Corp15.39bn1.05bn243.72bn202.00267.114.17101.1315.8311.0811.08185.73710.590.1582--11.8676,202,970.001.08--1.14--95.26--6.82----28.290.3392---12.10---62.44------
Sumitomo Pharma Co Ltd555.54bn-74.51bn258.71bn6.99k--0.6351--0.4657-187.55-187.551,398.331,023.800.45491.854.49---7.921.15-11.211.6767.7972.17-17.412.540.7713--0.451441.44-0.80193.54-232.08--0.62043.13
Peptidream Inc31.40bn8.13bn306.56bn569.0037.759.6229.099.7662.4662.46241.58245.030.56134.635.8355,178,160.0014.54--16.61--64.78--25.91--2.393.950.386--184.99--193.57------
Hisamitsu Pharmaceutical Co Inc128.33bn11.74bn308.55bn2.77k24.531.1018.072.40147.71147.711,616.133,297.550.41613.153.3046,345,250.003.934.614.515.2356.6559.969.4510.774.23--0.008849.516.77-2.8721.58-9.2918.810.4831
Data as of Jun 09 2023. Currency figures normalised to Sosei Group Corp's reporting currency: Japanese Yen JPY

Institutional shareholders

27.32%Per cent of shares held by top holders
HolderShares% Held
Taiyo Pacific Partners LPas of 01 Feb 20236.73m8.22%
Asset Management One Co., Ltd.as of 28 Apr 20234.24m5.17%
Capital International KKas of 15 Apr 20222.92m3.56%
Norges Bank Investment Managementas of 31 Dec 20221.45m1.77%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 01 May 20231.33m1.62%
JPMorgan Asset Management (Japan) Ltd.as of 15 May 20231.30m1.59%
Ichiyoshi Asset Management Co., Ltd.as of 29 Jun 20221.25m1.53%
Capital Research & Management Co. (World Investors)as of 15 Apr 20221.19m1.45%
BlackRock Fund Advisorsas of 04 May 20231.03m1.26%
Nikko Asset Management Co., Ltd.as of 02 May 2023933.90k1.14%
More ▼
Data from 19 Dec 2022 - 06 Apr 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.